103 related articles for article (PubMed ID: 11851612)
1. The role of volume-weighted mean nuclear volume in predicting tumour biology and clinical behaviour in patients with prostate cancer undergoing watchful waiting.
Arai Y; Egawa S; Kuwao S; Ogura K; Baba S
BJU Int; 2001 Dec; 88(9):909-14. PubMed ID: 11851612
[TBL] [Abstract][Full Text] [Related]
2. Volume-weighted mean nuclear volume predicts tumor biology of clinically organ-confined prostate cancer.
Arai Y; Okubo K; Terada N; Matsuta Y; Egawa S; Kuwao S; Ogura K
Prostate; 2001 Feb; 46(2):134-41. PubMed ID: 11170141
[TBL] [Abstract][Full Text] [Related]
3. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.
McLaren DB; McKenzie M; Duncan G; Pickles T
Cancer; 1998 Jan; 82(2):342-8. PubMed ID: 9445192
[TBL] [Abstract][Full Text] [Related]
4. Impact of volume weighted mean nuclear volume on outcomes following salvage radiation therapy after radical prostatectomy.
Matsui Y; Ichioka K; Terada N; Yoshimura K; Terai A; Dodo Y; Arai Y
J Urol; 2004 Feb; 171(2 Pt 1):687-91. PubMed ID: 14713787
[TBL] [Abstract][Full Text] [Related]
5. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
6. The role of volume-weighted mean nuclear volume in predicting disease outcome in patients with stage M1 prostate cancer.
Fujikawa K; Aoyama T; Itoh T; Nishio Y; Miyakawa M; Sasaki M
APMIS; 1999 Apr; 107(4):395-400. PubMed ID: 10230693
[TBL] [Abstract][Full Text] [Related]
7. The role of volume-weighted mean nuclear volume in predicting disease outcome in patients with prostate cancer treated with radical prostatectomy.
Fujikawa K; Itoh T; Nishio Y; Miyakawa M; Sasaki M
APMIS; 1999 Aug; 107(8):773-8. PubMed ID: 10515128
[TBL] [Abstract][Full Text] [Related]
8. Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations.
Ross PL; Mahmud S; Stephenson AJ; Souhami L; Tanguay S; Aprikian AG
Urology; 2004 Aug; 64(2):323-8. PubMed ID: 15302488
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification after radical prostatectomy in men with pathologically organ-confined prostate cancer using volume-weighted mean nuclear volume.
Matsui Y; Utsunomiya N; Ichioka K; Ueda N; Yoshimura K; Terai A; Arai Y
Prostate; 2005 Aug; 64(3):217-23. PubMed ID: 15712275
[TBL] [Abstract][Full Text] [Related]
11. Combining volume-weighted mean nuclear volume with Gleason score and clinical stage to predict more reliably disease outcome of patients with prostate cancer.
Fujikawa K; Sasaki M; Itoh T; Arai Y; Ogawa O; Yoshida O
Prostate; 1998 Oct; 37(2):63-9. PubMed ID: 9759699
[TBL] [Abstract][Full Text] [Related]
12. Predicting pathological stage of localized prostate cancer using volume weighted mean nuclear volume.
Fujikawa K; Matsui Y; Kobayashi T; Miura K; Oka H; Fukuzawa S; Takeuchi H
J Urol; 2000 Nov; 164(5):1587-90. PubMed ID: 11025710
[TBL] [Abstract][Full Text] [Related]
13. Prognostic criteria in patients with prostate cancer: Gleason score versus volume-weighted mean nuclear volume.
Fujikawa K; Sasaki M; Arai Y; Yamabe H; Ogawa O; Yoshida O
Clin Cancer Res; 1997 Apr; 3(4):613-8. PubMed ID: 9815728
[TBL] [Abstract][Full Text] [Related]
14. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy.
de Vries SH; Raaijmakers R; Kranse R; Blijenberg BG; Schröder FH
J Urol; 2004 Dec; 172(6 Pt 1):2193-6. PubMed ID: 15538230
[TBL] [Abstract][Full Text] [Related]
16. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.
Paller CJ; Olatoye D; Xie S; Zhou X; Denmeade SR; Eisenberger MA; Antonarakis ES; Carducci MA; Rosner GL
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):28-33. PubMed ID: 24100642
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer.
Thomsen FB; Christensen IJ; Brasso K; Røder MA; Iversen P
BJU Int; 2014 May; 113(5b):E98-105. PubMed ID: 24053601
[TBL] [Abstract][Full Text] [Related]
18. Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy.
Vasarainen H; Lahdensuo K; Savolainen R; Ruutu M; Taari K; Rannikko A
Scand J Urol; 2013 Dec; 47(6):456-61. PubMed ID: 23327661
[TBL] [Abstract][Full Text] [Related]
19. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer.
Stephenson AJ; Aprikian AG; Souhami L; Behlouli H; Jacobson AI; Bégin LR; Tanguay S
Urology; 2002 May; 59(5):652-6. PubMed ID: 11992834
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset.
Nam RK; Klotz LH; Jewett MA; Danjoux C; Trachtenberg J
Br J Urol; 1998 Jan; 81(1):100-4. PubMed ID: 9467484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
